Sugi Predict

Sugi Predict / Compounds / SCHEMBL30169991

SCHEMBL30169991

SCHEMBL30169991

CCOC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)COC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ CTSK P43235 6/20 0.38
▸ CTSS P25774 1/20 0.38
▸ CYP2D6 P10635 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15113948 0.83 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL17816452 0.83 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL15125088 0.83 CA1 (0.42) CA1CA2CA7CTSKCTSS
SCHEMBL3451633 0.83 CA1 (0.42) CA1CA2CA7CTSKCTSS
SCHEMBL21974625 0.82 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL28058637 0.82 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL26121174 0.78 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL20456829 0.77 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL12493568 0.76 SMN1; SMN2 (0.49) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL561366 0.75 CYP1A2 (0.55) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 — — US disclosed
CN-118159548-A Antiviral compounds 安力高医药股份有限公司 2024-06-07 — — CN disclosed
EP-4366831-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2024-05-15 — — EP disclosed
US-20240109871-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-04-04 — — US disclosed
US-11851422-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. 2023-12-26 — — US disclosed
US-20230093249-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-03-23 — — US disclosed
WO-2023283256-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2023-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CYP1A2 3530/4885CYP2C9 2985/4885CYP2C19 2576/4885
US-20230093249-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CYP1A2 3530/4885CYP2C9 2985/4885CYP2C19 2576/4885
US-11851422-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 CYP1A2 3530/4885CYP2C9 2985/4885CYP2C19 2576/4885
US-20240109871-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 CYP1A2 3530/4885CYP2C9 2985/4885CYP2C19 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.